- Case Report
- Open Access
Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib
© Stacchiotti et al.; licensee BioMed Central Ltd. 2013
- Received: 4 March 2013
- Accepted: 7 May 2013
- Published: 13 May 2013
Pigmented villonodular synovitis (PVNS) is a rare locally aggressive tumor. PVNS is characterized in most cases by a specific t(1;2) translocation, which fuses the colony stimulating factor-1 (CSF1) gene to the collagen type VIa3 (COL6A3) promoter thus leading through a paracrine effect to the attraction of non-neoplastic inflammatory cells expressing CSF1-receptor. Imatinib is a tirosin-kinase inhibitors (TKI) active against CSF1-receptor whose activity in naïve PVNS was already described. We report on two PVNS patients who responded to imatinib after failure to nilotinib, another CSF1-receptor inhibitor.
Since August 2012, 2 patients with progressive, locally advanced PVNS resistant to nilotinib (Patient 1: man, 34 years; Patient 2: woman, 24 years) have been treated with second-line imatinib 400 mg/day. Both patients are evaluable for response.
Both patients are still on treatment (7 and 4 months). Patient 1 had a dimensional response by MRI after 2 months from starting imatinib, together with symptomatic improvement. In Patient 2 a metabolic response was detected by [18F]fluorodeoxyglucose–positron emission tomography (PET) at 6 weeks coupled with tumor shrinkage by MRI, and symptomatic improvement.
Imatinib showed antitumor activity in 2 patients with nilotinib-resistant PVNS. This observation strengthen the idea that targeted agent with similar profile can give a different clinical result, as already described for gastrointestinal stromal tumor (GIST) patients treated with the same agents. Molecular studies are needed to clarify the biologic mechanism(s) underlying the response.
- Pigmented villonodular synovitis
- Targeted therapy
Pigmented villonodular synovitis (PVNS) is a rare locally aggressive tumors which generally arise from the synovium in the knee and foot of young individuals. Standard treatment is surgery, but in a proportion of cases surgery fails to obtain definitive disease control . Even if PVNS is a locally destructive benign process and very few patients die of the disease, the resulting functional impairments can be substantial. The activity of imatinib in PVNS was first reported by Blay et al. in 2008 , and confirmed thereafter in a retrospective series of 27 patients, with RECIST partial response (PR) in 19% and stable disease in 74% . Imatinib antitumor effect is thought to be mediated by blockade of the colony stimulating factor-1 receptor (CSF1R). In fact, colony stimulating factor-1 (CSF1), i.e. CSF1R ligand, is overexpressed in PVNS due to a specific t(1;2) translocation, which fuses the CSF1 gene to the collagen type VI a3 (COL6A3) promoter. CSF1, in turn, attracts non-neoplastic inflammatory cells expressing the CSF1 receptor (CSF1R) through a paracrine effect . CSF1 is an inflammatory mediator which is present together with its receptor (CSF1R) in human synovia. Notably, CSF1 expression was demonstrated at protein and mRNA level both in translocated and in non translocated PVNS .
This analysis was approved by the Institutional Ethics Committee.
We report on objective tumor responses we observed in two patients with locally advanced diffuse-type PVNS whom we treated with imatinib following lack of response to nilotinib. In the first case, response to imatinib was observed in a patient that initially got a tumor disease stabilization under nilotinib and further progressed (i.e. secondary resistance to nilotinib), while the second patient never responded to nilotinib (i.e. primary resistance to nilotinib).
Imatinib is a tyrosine-kinase inhibitor with activity against BCR-ABL, KIT, PDGFR, FLT3, RET, and CSFR1. No prospective studies on imatinib in PVNS are available, while a European phase 2 study on nilotinib, another CSF1R inhibitor, was completed in 2012, and results were preliminarily reported with . At a median follow-up of about 10 months, best response was a RECIST PR in one out of 49 patients treated with nilotinib (7%), for a 12-week progression free rate (PFR) of 88.9%. The assumption was that the two agents would have displayed the same pattern of antitumor activity in this rare disease, given their similar molecular profile and their ability to inhibit CSFR1 at similar concentrations . However, the observation of tumor responses to imatinib in nilotinib-resistant PVNS patients is challenging and deserve further investigations.
One hypothesis may be a less favorable pharmakokinetics of nilotinib in these patients, compared to imatinib. Besides, a molecular investigation of these patients would be very helpful to look at polymorphisms of other targets of imatinib and nilotinib in particular KIT and PDGFR. Indirect effects of imatinib on tumor progression, mediated by specific activities on tyrosine kinase receptors other than CSM1R cannot be excluded in these models. In fact, also PDGFRB was found to be activated in the two cases we describe here. This differential activity of imatinib and nilotinib may also be related to differential biochemical activity of these agents on CSFR1. Indeed the side effect profile of nilotinib and imatinib are slightly different, eg with more periorbital oedema with imatinib. This indicates that imatinib has a differential activity on some targets, including possibly CSFR1. Finally, the immune response hypothesis should be also evaluated. In fact, CSFR1 is an inflammatory mediator and can work also as quite a potent blocker of the immune response through the dendritic cells , and the NK cells . In addition to selectively inhibit the tumor cells, imatinib was found to be able to induce indirect effects on immune system by stimulating autoimmune response. Therefore, it is tempting to speculate that the action of imatinib in PVNS could be also related to this indirect effect, already reported for gastrointestinal stromal tumor (GIST) patients [10, 11]. In diffuse-type PVNS this effect could be even more relevant given the significant amount of inflammatory component detectable in this disease.
A tumor response to imatinib was seen in two patients with progressive nilotinib-resistant PVNS.
This observation strengthen the notion that targeted agents with an expected similar molecular profile can show a different clinical activity, as already described for GIST patients treated with the same agents. Molecular studies are needed to better understand the molecular basis for the activity of imatinib in this disease.
Written informed consent was obtained from the patients for publication of this Case Report and any accompanying legend. A copy of the written informed consents are available for review by the Editor-in-Chief of this journal
- Mankin H, Trahan C, Hornicek F: Pigmented villonodular synovitis of joints. J Surg Oncol. 2011, 103: 386-389. 10.1002/jso.21835View ArticlePubMedGoogle Scholar
- Blay JY, El Sayadi H, Thiesse P: Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol. 2008, 19: 821-822.View ArticlePubMedGoogle Scholar
- Cassier PA, Gelderblom H, Stacchiotti S: Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer. 2012, 118: 1649-1655. 10.1002/cncr.26409View ArticlePubMedGoogle Scholar
- West RB, Rubin BP, Miller MA: A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA. 2006, 103: 690-695. 10.1073/pnas.0507321103PubMed CentralView ArticlePubMedGoogle Scholar
- Cupp JS, Miller MA, Montgomery KD: Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol. 2007, 31: 970-976. 10.1097/PAS.0b013e31802b86f8View ArticlePubMedGoogle Scholar
- Ray-Coquard I, Gelderblom H, Chevreau C: An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment. J Clin Oncol. 2012, 30 (15 Suppl 1):Google Scholar
- Brownlow N, Russell AE, Saravanapavan H: Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis. Leukemia. 2008, 22: 649-52. 10.1038/sj.leu.2404944View ArticlePubMedGoogle Scholar
- Menetrier-Caux C, Montmain G, Dieu MC: Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood. 1998, 92: 4778-91.PubMedGoogle Scholar
- Borg C, Terme M, Taïeb J: Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest. 2004, 114: 379-88.PubMed CentralView ArticlePubMedGoogle Scholar
- Ménard C, Blay JY, Borg C: Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res. 2009, 69: 3563-9. 10.1158/0008-5472.CAN-08-3807View ArticlePubMedGoogle Scholar
- Zitvogel L, Kroemer G: Anticancer effect of imatinib via immunostimulation. Nat Med. 2011, 17: 1050-1. 10.1038/nm.2429View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.